Joseph S. McCracken - Aug 11, 2021 Form 4 Insider Report for LUMOS PHARMA, INC. (LUMO)

Role
Director
Signature
/s/ Ryan Trytten, attorney-in-fact
Stock symbol
LUMO
Transactions as of
Aug 11, 2021
Transactions value $
$56,406
Form type
4
Date filed
8/13/2021, 04:31 PM
Previous filing
May 24, 2021
Next filing
Aug 30, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LUMO Common Stock Purchase $56.4K +7.48K +694.7% $7.55 8.55K Aug 11, 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.475 to $7.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in this footnote to this Form 4.
F2 Includes 473 restricted stock units ("RSUs") previously reported as holdings of the Reporting Person granted under the Issuer's 2010 Non-Employee Directors' Stock Award Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in a series of two successive annual installments with the next installment occurring on April 3, 2022, in each case subject to the Reporting Person's continuous service as of such date.